Disease Landscape and Forecast Insights

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is…

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain…

Chemotherapy has formed the backbone of oncology treatment for decades, and it continues to remain a critical cornerstone of antineoplastic drug therapy. The chemotherapy market is heavily…

China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved to treat this indication—Roche’s Herceptin as…

MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted…

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma— continues to rise; however, treatment options remain…

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant…

Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, three additional trastuzumab biosimilars…

Market Outlook Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and GEJ adenocarcinoma in the major pharmaceutical markets…

The genetic complexity and heterogeneity of gastric and GEJ adenocarcinoma poses a significant challenge for the development of treatment strategies for these cancers. Despite advancements in the…

Celltrion’s Herzuma (trastuzumab) is the first biosimilar of Roche’s blockbuster HER2-targeted therapy, Herceptin, to launch in Europe. This series tracks uptake of Herzuma and medical…

Market Outlook  Therapeutic options for gastroesophageal cancer are limited, with only two targeted agents approved for the treatment of gastric and GEJ adenocarcinoma (neither agent is approved…